+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF)

An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF)

Postgraduate Medical Journal 92(1094): 726-734

An estimated 5.1 million Americans have chronic heart failure and this is expected to increase 25% by 2030. Heart failure is a clinical syndrome that evolves from either functional or structural changes to the ventricles that lead to filling or ejection abnormalities. Thus far, pharmacotherapy has been show to be beneficial in patients only with reduced ejection fraction; however, new therapies have been developed in hopes of reducing the burden of heart failure. In this review, we will discuss current pharmacotherapies recommended in American College of Cardiology/American Heart Association guidelines, the evidence behind these recommendations as well as new and emerging therapies that have been developed.

(PDF emailed within 0-6 h: $19.90)

Accession: 057180482

Download citation: RISBibTeXText

PMID: 27708003

DOI: 10.1136/postgradmedj-2016-134378

Related references

Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF). Heart and Vessels 33(4): 403-412, 2017

A practical guide for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF). Current Cardiology Reviews 11(1): 23-32, 2015

Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?. Clinical Pharmacology and Therapeutics 103(5): 802-814, 2018

Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry. Journal of the Chinese Medical Association 80(12): 750-757, 2017

Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. Plos One 9(6): E99495, 2015

Effect of a 6-month pedometer-based walking intervention on functional capacity in patients with chronic heart failure with reduced (HFrEF) and with preserved (HFpEF) ejection fraction: study protocol for two multicenter randomized controlled trials. Journal of Translational Medicine 15(1): 153, 2018

Mortality of Patients with Heart Failure and Reduced Ejection Fraction (HFrEF) Who Receive Either ICD or CRT-D Has Improved Yearly from 2003 to 2010: The Altitude Registry. Journal of Cardiac Failure 19(8): S21-S22, 2013

Impact of Exhaled Breath Acetone in the Prognosis of Patients with Heart Failure with Reduced Ejection Fraction (HFrEF). One Year of Clinical Follow-up. Plos One 11(12): E0168790, 2017

The safety and tolerability of beta blockers in heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified?. Expert Opinion on Drug Safety 14(12): 1855-1863, 2016

"Evaluation of chronic obstructive pulmonary disease (COPD) and reduced ejection fraction heart failure (HFrEF) discharge medication prescribing: Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions?" [Respir. Med. 119 (October 2016) 135-140. Respiratory Medicine 123: 150, 2016

Determinants of Left Ventricular Systolic Function Improvement Following Coronary Artery Revascularization in Heart Failure Patients With Reduced Ejection Fraction (HFrEF). International Heart Journal 57(5): 565-572, 2017

Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments. Swiss Medical Weekly 146: W14295, 2016

Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study. JAMA Cardiology 2(5): 536-546, 2017

Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. Esc Heart Failure 5(4): 685-694, 2018

Short and long-term prognostic value of hyponatremia in heart failure with preserved ejection fraction versus reduced ejection fraction: An analysis of the Korean Acute Heart Failure registry. International Journal of Cardiology 248: 239-245, 2017